Relapsed Refractory Multiple Myeloma
Oncology
3
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Karyopharm TherapeuticsNEWTON, MA
1 program1
Abemaciclib, dexamethasone, ixazomib, pomalidomidePhase 1/2
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
AmgenDrug: Carfilzomib + Dexamethasone
AstraZenecaAZD0120
Clinical Trials (2)
Total enrollment: 609 patients across 2 trials
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Start: Sep 2019Est. completion: Jun 2025101 patients
Phase 4Completed
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Start: Feb 2026Est. completion: Jul 2030508 patients
Phase 3Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
2h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
2h ago
Office Administrator
SystImmune
2h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
3h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
3h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
3h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 609 patients
3 companies competing in this space